Companies / DVL

DORSAVI LTD

ASX:DVLPharmaceuticals, Biotechnology & Life Sciences
1.24B shares on issueASX (delayed) · as of 28 July 2026$0.028price · delayed$34.6Mmarket cap · indicative
F
Dilution grade

Runway under 2 quarters; share count grew 104% in 24 months; options/rights overhang 33% of shares

Cash runway0.3 quarters of funding
Share-count growth (24m)103.6%
Raise cadence (24m)2 cash raises
Options & rights overhang32.9% of shares
In-the-money supply14.4% of shares
Pending proposed issuesopen proposed issue (Appendix 3B)

DORSAVI LTD's ordinary share count grew 103.6% between June 2024 and June 2026, to 1.24B shares. The company raised capital twice in that period for total proceeds of A$7.4M, most recently A$5.0M in August 2025. Options and rights on issue could convert into 406M new shares, equal to 32.9% of the current share count, of which 14% are in the money; the nearest expiry is August 2027. At the March 2026 quarter DORSAVI reported A$560K in available cash, covering about 0.3 quarters at its recent spending rate. One proposed securities issue (Appendix 3B) is pending with an expected issue date in July 2026.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
32.9%
Max option dilution
14.4%
ITM option dilution
1
Raises · last 12 months
0.3 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 1.24B per ASX (delayed) (28 July 2026).
0.84B0.98B1.13BDec 24Sept 25July 26Cash raise · 15 Aug 2025Cash raise · 6 June 2025

Cash runway

0.3 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$560k available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
14 July 20263H · cancellationDVL : ORDINARY FULLY PAID1.24BAppendix 3H
15 June 20262A · quoted issueDVL : ORDINARY FULLY PAID1.24BAppendix 2A
9 Apr 20263H · cancellationDVL : ORDINARY FULLY PAID1.21BAppendix 3H
27 Feb 20262A · quoted issueDVL : ORDINARY FULLY PAID1.21BAppendix 2A
13 Feb 20263G · unquotedORDINARY FULLY PAID1.13BAppendix 3G
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

2 cash raises in the last 24 months · 1 in the last 12 months

$5.0M
Capital raise
15 Aug 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

1 proposed issue pending — Appendix 3B lodged, securities not yet issued. New shares from these issues are not in the counts above until quoted.
Paid plan
Pending issue detail
Size, price, fees, broker and placement-capacity usage for each pending issue.
Join the waitlist

Options & convertible securities

32.9%
Total overhang · of current shares
14.4%
In the money · at current price
406.2M
Potential new shares
Aug 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
13 Feb 2026Gernot AblOther———3Y notice
20 Aug 2025Gernot AblOther—4.5M—3Y notice
20 Aug 2025Leigh TraversOther—1.8M—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

27 July 2026$PdorsaVi v6.5 Sensor Advances Physical AI Strategy
14 July 2026$PdorsaVi Commences Tape-Out of Validation Chip
14 July 2026Notification of cessation of securities - DVL
17 June 2026$PdorsaVi Finalises RRAM-CMOS Validation Chip Design
15 June 2026Section 708A Cleansing Notice
15 June 2026Application for quotation of securities - DVL
14 June 2026$PdorsaVi Well Funded Following $500k Options Exercise
9 June 2026Proposed issue of securities - DVL
9 June 2026$PdorsaVi Licenses Human Robot Collaboration IP
3 June 2026$PRRAM Tech Evaluation Indicates 2x Battery Life in Robotics
31 May 2026$PDVL RRAM Showcases Stable Performance in Temperature Testing
18 May 2026DVL May 2026 Investor Webinar
17 May 2026$PDVL Marks Major Milestone to 22nm RRAM Commercialisation
10 May 2026$PDVL Advances US Dept of Defense Military Injury Program
5 May 2026$PDVL advances modular ultra-edge hardware platform
29 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
27 Apr 2026$PDVL Expands Robotics Strategy into Next-Gen Exoskeletons
20 Apr 2026$PRRAM-Neuromorphic Fusion Drives Robotics, Exoskeletons Gains
10 Apr 2026Change of Company Auditor
9 Apr 2026Notification of cessation of securities - DVL

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.